1.47

3.52% 0.05

After Hours: 1.48 0.01 +0.68%

Atai Life Sciences N V (ATAI)

Overview News Price History Option Chain Financials Discussions Forecast

Atai Life Sciences N V stock is traded at $1.47, with a volume of 1.66M. It is up +3.52% in the last 24 hours and up +0.68% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Previous Close:

$1.42

Open:

$1.44

24h Volume:

1.66M

Relative Volume:

0.63

Market Cap:

$273.66M

Revenue:

$314.00K

Net Income/Loss:

$-40.23M

P/E Ratio:

-5.25

EPS:

-0.28

Net Cash Flow:

$-84.71M

1W Performance:

+21.49%

1M Performance:

+0.68%

6M Performance:

+22.50%

1Y Performance:

-25.76%

1-Day Range:

$1.42

$1.51

1-Week Range:

$1.1927

$1.51

52-Week Range:

$1.03

$2.565

Atai Life Sciences N V Stock (ATAI) Company Profile

Name

Atai Life Sciences N V

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

49 89 2153 9035

Address

WALLSTRASSE 16, BERLIN

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATAI Atai Life Sciences N V	1.47	273.66M	314.00K	-40.23M	-84.71M	-0.28
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy
Apr-03-24	Upgrade	Maxim Group	Hold → Buy
Nov-01-22	Initiated	Loop Capital	Buy
Nov-30-21	Initiated	Maxim Group	Buy
Nov-11-21	Initiated	ROTH Capital	Buy
Oct-18-21	Initiated	H.C. Wainwright	Buy
Sep-01-21	Initiated	Jefferies	Buy
Jul-13-21	Initiated	Berenberg	Buy
Jul-13-21	Initiated	Canaccord Genuity	Buy
Jul-13-21	Initiated	Cantor Fitzgerald	Buy
Jul-13-21	Initiated	Citigroup	Buy
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Credit Suisse	Outperform
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform
Jul-08-21	Initiated	Aegis Capital	Buy

View All

Atai Life Sciences N V Stock (ATAI) Latest News

Apr 15, 2025

At What Point In Time Would I Choose To Purchase ATAI Life Sciences N.V (NASDAQ: ATAI) Stock? - stocksregister.com

Apr 15, 2025

Apr 14, 2025

Psychedelic Drugs Market Future Business Opportunities - openPR.com

Apr 14, 2025

Apr 05, 2025

Berenberg starts atai Life Sciences coverage with Positive rating By Investing.com - Investing.com Australia

Apr 05, 2025

Apr 04, 2025

Berenberg starts atai Life Sciences coverage with Positive rating - Investing.com India

Apr 04, 2025

Mar 31, 2025

How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com

Mar 31, 2025

Mar 26, 2025

Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.

Mar 26, 2025

Mar 25, 2025

Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com UK

Mar 25, 2025

Mar 24, 2025

Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa

Mar 24, 2025

Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa

Mar 24, 2025

Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa

Mar 24, 2025

Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa

Mar 24, 2025

Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India

Mar 24, 2025

Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India

Mar 24, 2025

Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India

Mar 24, 2025

Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India

Mar 24, 2025

Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK

Mar 24, 2025

Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com

Mar 24, 2025

Mar 21, 2025

Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance

Mar 21, 2025

Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews

Mar 21, 2025

Mar 20, 2025

ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 17, 2025

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times

Mar 17, 2025

Mar 13, 2025

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks

Mar 13, 2025

Mar 11, 2025

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance

Mar 11, 2025

Mar 04, 2025

Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025

Mar 03, 2025

How is ATAI’s stock performing after recent trades? - US Post News

Mar 03, 2025

Mar 01, 2025